209 related articles for article (PubMed ID: 34154646)
1. Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma.
Genovesi LA; Millar A; Tolson E; Singleton M; Hassall E; Kojic M; Brighi C; Girard E; Andradas C; Kuchibhotla M; Bhuva DD; Endersby R; Gottardo NG; Bernard A; Adolphe C; Olson JM; Taylor MD; Davis MJ; Wainwright BJ
Genome Med; 2021 Jun; 13(1):103. PubMed ID: 34154646
[TBL] [Abstract][Full Text] [Related]
2. Developmental phosphoproteomics identifies the kinase CK2 as a driver of Hedgehog signaling and a therapeutic target in medulloblastoma.
Purzner T; Purzner J; Buckstaff T; Cozza G; Gholamin S; Rusert JM; Hartl TA; Sanders J; Conley N; Ge X; Langan M; Ramaswamy V; Ellis L; Litzenburger U; Bolin S; Theruvath J; Nitta R; Qi L; Li XN; Li G; Taylor MD; Wechsler-Reya RJ; Pinna LA; Cho YJ; Fuller MT; Elias JE; Scott MP
Sci Signal; 2018 Sep; 11(547):. PubMed ID: 30206138
[TBL] [Abstract][Full Text] [Related]
3. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
[TBL] [Abstract][Full Text] [Related]
4. Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
Gordon RE; Zhang L; Peri S; Kuo YM; Du F; Egleston BL; Ng JMY; Andrews AJ; Astsaturov I; Curran T; Yang ZJ
Clin Cancer Res; 2018 Mar; 24(6):1375-1388. PubMed ID: 29437795
[No Abstract] [Full Text] [Related]
5. The rationale for targeted therapies in medulloblastoma.
MacDonald TJ; Aguilera D; Castellino RC
Neuro Oncol; 2014 Jan; 16(1):9-20. PubMed ID: 24305711
[TBL] [Abstract][Full Text] [Related]
6. An ABC Transporter Drives Medulloblastoma Pathogenesis by Regulating Sonic Hedgehog Signaling.
Wijaya J; Vo BT; Liu J; Xu B; Wu G; Wang Y; Peng J; Zhang J; Janke LJ; Orr BA; Yu J; Roussel MF; Schuetz JD
Cancer Res; 2020 Apr; 80(7):1524-1537. PubMed ID: 31948942
[TBL] [Abstract][Full Text] [Related]
7. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets.
Hanaford AR; Archer TC; Price A; Kahlert UD; Maciaczyk J; Nikkhah G; Kim JW; Ehrenberger T; Clemons PA; Dančík V; Seashore-Ludlow B; Viswanathan V; Stewart ML; Rees MG; Shamji A; Schreiber S; Fraenkel E; Pomeroy SL; Mesirov JP; Tamayo P; Eberhart CG; Raabe EH
Clin Cancer Res; 2016 Aug; 22(15):3903-14. PubMed ID: 27012813
[TBL] [Abstract][Full Text] [Related]
8. Functional Precision Medicine Identifies New Therapeutic Candidates for Medulloblastoma.
Rusert JM; Juarez EF; Brabetz S; Jensen J; Garancher A; Chau LQ; Tacheva-Grigorova SK; Wahab S; Udaka YT; Finlay D; Seker-Cin H; Reardon B; Gröbner S; Serrano J; Ecker J; Qi L; Kogiso M; Du Y; Baxter PA; Henderson JJ; Berens ME; Vuori K; Milde T; Cho YJ; Li XN; Olson JM; Reyes I; Snuderl M; Wong TC; Dimmock DP; Nahas SA; Malicki D; Crawford JR; Levy ML; Van Allen EM; Pfister SM; Tamayo P; Kool M; Mesirov JP; Wechsler-Reya RJ
Cancer Res; 2020 Dec; 80(23):5393-5407. PubMed ID: 33046443
[TBL] [Abstract][Full Text] [Related]
9. Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma.
Brun SN; Markant SL; Esparza LA; Garcia G; Terry D; Huang JM; Pavlyukov MS; Li XN; Grant GA; Crawford JR; Levy ML; Conway EM; Smith LH; Nakano I; Berezov A; Greene MI; Wang Q; Wechsler-Reya RJ
Oncogene; 2015 Jul; 34(29):3770-9. PubMed ID: 25241898
[TBL] [Abstract][Full Text] [Related]
10. CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway.
Chen J; Lv H; Hu J; Ji M; Xue N; Li C; Ma S; Zhou Q; Lin B; Li Y; Yu S; Chen X
Cancer Lett; 2016 Oct; 381(2):391-403. PubMed ID: 27495899
[TBL] [Abstract][Full Text] [Related]
11. Medulloblastoma: Molecular understanding, treatment evolution, and new developments.
Liu X; Ding C; Tan W; Zhang A
Pharmacol Ther; 2020 Jun; 210():107516. PubMed ID: 32105673
[TBL] [Abstract][Full Text] [Related]
12. Systems biology-based drug repositioning identifies digoxin as a potential therapy for groups 3 and 4 medulloblastoma.
Huang L; Garrett Injac S; Cui K; Braun F; Lin Q; Du Y; Zhang H; Kogiso M; Lindsay H; Zhao S; Baxter P; Adekunle A; Man TK; Zhao H; Li XN; Lau CC; Wong STC
Sci Transl Med; 2018 Oct; 10(464):. PubMed ID: 30355798
[TBL] [Abstract][Full Text] [Related]
13. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
Li Y; Song Q; Day BW
Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
[TBL] [Abstract][Full Text] [Related]
14. Medulloblastoma cancer stem cells: molecular signatures and therapeutic targets.
Bahmad HF; Poppiti RJ
J Clin Pathol; 2020 May; 73(5):243-249. PubMed ID: 32034059
[TBL] [Abstract][Full Text] [Related]
15. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma.
Shou Y; Robinson DM; Amakye DD; Rose KL; Cho YJ; Ligon KL; Sharp T; Haider AS; Bandaru R; Ando Y; Geoerger B; Doz F; Ashley DM; Hargrave DR; Casanova M; Tawbi HA; Rodon J; Thomas AL; Mita AC; MacDonald TJ; Kieran MW
Clin Cancer Res; 2015 Feb; 21(3):585-93. PubMed ID: 25473003
[TBL] [Abstract][Full Text] [Related]
16. A Novel Combination Approach Targeting an Enhanced Protein Synthesis Pathway in MYC-driven (Group 3) Medulloblastoma.
Chaturvedi NK; Kling MJ; Griggs CN; Kesherwani V; Shukla M; McIntyre EM; Ray S; Liu Y; McGuire TR; Sharp JG; Band H; Joshi SS; Coulter DW
Mol Cancer Ther; 2020 Jun; 19(6):1351-1362. PubMed ID: 32371591
[TBL] [Abstract][Full Text] [Related]
17. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of the FACT Complex Targets Aberrant Hedgehog Signaling and Overcomes Resistance to Smoothened Antagonists.
Mo J; Liu F; Sun X; Huang H; Tan K; Zhao X; Li R; Jiang W; Sui Y; Chen X; Shen K; Zhang L; Ma J; Zhao K; Tang Y
Cancer Res; 2021 Jun; 81(11):3105-3120. PubMed ID: 33853831
[TBL] [Abstract][Full Text] [Related]
19. Smoothened-activating lipids drive resistance to CDK4/6 inhibition in Hedgehog-associated medulloblastoma cells and preclinical models.
Daggubati V; Hochstelter J; Bommireddy A; Choudhury A; Krup AL; Kaur P; Tong P; Li A; Xu L; Reiter JF; Raleigh DR
J Clin Invest; 2021 Mar; 131(6):. PubMed ID: 33476305
[TBL] [Abstract][Full Text] [Related]
20. Neogenin1 is a Sonic Hedgehog target in medulloblastoma and is necessary for cell cycle progression.
Milla LA; Arros A; Espinoza N; Remke M; Kool M; Taylor MD; Pfister SM; Wainwright BJ; Palma V
Int J Cancer; 2014 Jan; 134(1):21-31. PubMed ID: 23775842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
